Progress and Hurdles of Therapeutic Nanosystems against Cancer
Metadatos
Afficher la notice complèteAuteur
Martín Contreras, Marina; Navarro Marchal, Saul Abenhamar; Peula García, José Manuel; Jódar Reyes, Ana BelénEditorial
MDPI
Materia
Nanomedicine Design of nanosystems Physicochemical properties Protein corona Targeting Delivery Clinical application
Date
2022-02-10Referencia bibliográfica
Martín-Contreras, M... [et al.]. Progress and Hurdles of Therapeutic Nanosystems against Cancer. Pharmaceutics 2022, 14, 388. [https://doi.org/10.3390/pharmaceutics14020388]
Patrocinador
FEDER/Junta de Andalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades PY20_00241 A-FQM-90-UGR20Résumé
Nanomedicine against cancer, including diagnosis, prevention and treatment, has increased
expectations for the solution of many biomedical challenges in the fight against this disease. In recent
decades, an exhaustive design of nanosystems with high specificity, sensitivity and selectivity has
been achieved due to a rigorous control over their physicochemical properties and an understanding
of the nano–bio interface. However, despite the considerable progress that has been reached in this
field, there are still different hurdles that limit the clinical application of these nanosystems, which,
along with their possible solutions, have been reviewed in this work. Specifically, physiological
processes as biological barriers and protein corona formation related to the administration routes,
designing strategies to overcome these obstacles, promising new multifunctional nanotherapeutics,
and recent clinical trials are presented in this review.